Glucose dysregulation in patients with iron overload: is there a relationship with quantitative pancreas and liver iron and fat content measured by MRI?
Diabetes mellitus
Iron
Magnetic resonance imaging
Pancreas
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
27
06
2019
accepted:
09
10
2019
revised:
27
08
2019
pubmed:
13
11
2019
medline:
1
9
2020
entrez:
13
11
2019
Statut:
ppublish
Résumé
The aim was to investigate the relationship between pancreatic and hepatic iron and fat to glucose metabolism in patients with iron overload and address conflicting results in literature as regards the relationship between pancreas iron and glucose dysregulation. We retrospectively evaluated pancreatic and hepatic R2*, fat fraction (FF), liver iron concentration (LIC), and glucose metabolism in 105 patients with iron overload obtained with a multi-echo gradient echo R2* technique and assessed the correlation between pancreatic R2* and FF to glucose dysregulation. There were no significant differences in pancreatic R2*, liver R2*, and FF in patients with iron overload and glucose dysregulation compared to those with normoglycemia (p = 0.435, p = 0.674, and p = 0.976), whereas pancreatic FF was significantly higher, 23.5% vs 16.7% respectively (p = 0.011). Pancreatic FF and R2* demonstrated an area under the curve of 0.666 and 0.571 for discriminating glucose dysregulation. Pancreatic FF of 26.2% yielded specificity and sensitivity of 80% and 45% for prediction of glucose dysregulation. Pancreatic R2* weakly correlated with pancreatic FF, r = 0.388 (p < 0.001), and liver R2*, r = 0.201 (p = 0.033), and showed no correlation with hepatic FF r = -0.013 (p = 0.892) or LIC categories (p = 0.493). Pancreatic FF but not pancreatic R2* was associated with glucose dysregulation in patients with iron overload. Prior studies reporting correlation of pancreatic R2* to glucose dysregulation likely relate from inadequate MRI technique or analysis employed, which unlike our study did not perform simultaneous measurements of fat and iron essential to avoid their confounding effects during quantitative analysis. • Pancreatic fat fraction, unlike iron, is associated with glucose dysregulation in iron overload. • Simultaneous measurement of pancreatic iron and fat content with MRI is essential to avoid confounding effects of one another during quantitative analysis. • Pancreatic fat fraction could be utilized to predict glucose dysregulation in iron overload states.
Identifiants
pubmed: 31712958
doi: 10.1007/s00330-019-06487-z
pii: 10.1007/s00330-019-06487-z
doi:
Substances chimiques
Iron
E1UOL152H7
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1616-1623Références
Diabetes Care. 2007 Jul;30(7):1926-33
pubmed: 17429063
Hematology Am Soc Hematol Educ Program. 2004;:14-34
pubmed: 15561674
J Clin Endocrinol Metab. 2011 Jun;96(6):E958-61
pubmed: 21430023
Haematologica. 2004 Oct;89(10):1187-93
pubmed: 15477202
Magn Reson Med. 2008 Nov;60(5):1122-34
pubmed: 18956464
ISRN Hematol. 2013 Mar 28;2013:496985
pubmed: 23606980
N Engl J Med. 1994 Sep 1;331(9):567-73
pubmed: 8047080
N Engl J Med. 2005 Sep 15;353(11):1135-46
pubmed: 16162884
Eur Heart J. 2001 Dec;22(23):2171-9
pubmed: 11913479
Ann N Y Acad Sci. 2005;1054:40-7
pubmed: 16339650
Magn Reson Imaging. 2008 Apr;26(3):347-59
pubmed: 18093781
Dig Liver Dis. 2003 Mar;35(3):172-8
pubmed: 12779071
Am J Hematol. 2015 Sep;90(9):E189-90
pubmed: 26044155
Br J Haematol. 2006 Aug;134(4):438-44
pubmed: 16822284
Eur J Intern Med. 2016 Jul;32:31-7
pubmed: 27113814
Magn Reson Med. 2014 Jun;71(6):2215-23
pubmed: 23821350
Blood. 2008 Oct 1;112(7):2973-8
pubmed: 18650452
Blood. 2009 Nov 5;114(19):4021-6
pubmed: 19726718
Endocr Rev. 2008 Dec;29(7):939-60
pubmed: 18723451
Haematologica. 2008 Jan;93(1):116-9
pubmed: 18166794
Magn Reson Med. 2013 Dec;70(6):1765-74
pubmed: 23359410
PLoS One. 2017 Jul 24;12(7):e0180911
pubmed: 28742102
Hemoglobin. 2017 May;41(3):151-156
pubmed: 28762844
Diabetol Metab Syndr. 2010 Apr 15;2:23
pubmed: 20398341
Am J Hematol. 2012 Feb;87(2):155-60
pubmed: 22120775
Eur J Radiol. 2012 Jul;81(7):1465-70
pubmed: 21501938
Med Phys. 1985 Mar-Apr;12(2):232-3
pubmed: 4000083
Diabetes Care. 2015 Jan;38 Suppl:S8-S16
pubmed: 25537714
Pediatr Blood Cancer. 2014 Jan;61(1):20-4
pubmed: 24115521
J Hepatol. 2011 Oct;55(4):920-32
pubmed: 21718726
Blood. 2005 Jan 15;105(2):855-61
pubmed: 15256427
Eur Radiol. 2007 Dec;17(12):3025-30
pubmed: 17549485
Magn Reson Med. 2014 Nov;72(5):1353-65
pubmed: 24323332
Blood. 2005 Aug 15;106(4):1460-5
pubmed: 15860670
J Magn Reson Imaging. 2015 Jul;42(1):196-203
pubmed: 25236606
Eur Radiol. 2007 Jun;17(6):1535-43
pubmed: 17149622
Blood. 1997 Feb 1;89(3):739-61
pubmed: 9028304
Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:249-55
pubmed: 16462705
Am J Hematol. 2017 Oct;92(10):E620-E621
pubmed: 28707395
AJR Am J Roentgenol. 1999 Jul;173(1):187-92
pubmed: 10397124
J Pediatr Hematol Oncol. 2017 Jul;39(5):337-340
pubmed: 28085743